Investment in China | GenomeWeb

Investment in China

Merck isn't the first pharmaceutical company to invest in research in China, but it sure is spending a lot more, says ScienceInsider's Hao Xin. The company says it plans to spend about $1.5 billion on R&D in China over the next five years, starting with a staff of 260 in Beijing. Merck already has a commercial headquarters in Shanghai and has built manufacturing facilities in other parts of China, Xin says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.